Company / Cash & Equivalents
Mineralys Therapeutics, Inc. Cash & Equivalents History
FY2022-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$114.1M
FY2024
5-year range
$49.3M / $114.1M
FY2022-FY2024
Trend
+131.4%
vs FY2023
Sector context
#132 of 207
Health Care
What the data says
At $114M, Mineralys Therapeutics, Inc.'s cash & equivalents ranks #132 of 207 in the Health Care sector. Improved from $88M to $114M over the past 2 years.
Based on SEC 10-K filings.
$114M in FY2024.
Improved from $88M to $114M over the past 2 years.
Health Care sector context is included.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#132 of 207 in Health CareTop 64% of 207This company $114.1M Sector average $669.5M
▼
-83.0% below sector average
Key checks
Key Insights
- In FY2024, cash & equivalents increased 131.4% year-over-year.
- Ranks #132 out of 207 companies in the Health Care sector.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 3.25 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | $114.1M | +131.4% |
| FY2023 | $49.3M | -43.8% |
| FY2022 | $87.7M | - |
As of FY2024 · SEC 10-K · Updated Feb 28, 2026